Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Primary and Secondary Negative Symptoms in Schizophrenia
Sergey Mosolov, Polina A. Yaltonskaya
Frontiers in Psychiatry (2022) Vol. 12
Open Access | Times Cited: 72

Showing 1-25 of 72 citing articles:

Physical activity and prevention of mental health complications: An umbrella review
Masoud Rahmati, San Lee, Dong Keon Yon, et al.
Neuroscience & Biobehavioral Reviews (2024) Vol. 160, pp. 105641-105641
Open Access | Times Cited: 23
Cerebellar Contributions to the Basal Ganglia Influence Motor Coordination, Reward Processing, and Movement Vigor
Junichi Yoshida, Maritza Oñate, Leila Khatami, et al.
Journal of Neuroscience (2022) Vol. 42, Iss. 45, pp. 8406-8415
Open Access | Times Cited: 53
Roles of the Oxytocin Receptor (OXTR) in Human Diseases
Karolina Pierzynowska, Lidia Gaffke, Magdalena Żabińska, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 3887-3887
Open Access | Times Cited: 30
Smoking affects symptom improvement in schizophrenia: a prospective longitudinal study of male patients with first-episode schizophrenia
Xishu Mu, Wenjing Wu, Sisi Wang, et al.
Schizophrenia (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 8
Therapeutic Potential of DAAO Inhibitors for Cognitive Impairment Associated with Schizophrenia: Learnings from Luvadaxistat
Ryan T. Terry-Lorenzo, Ruicheng Fan, Ni A. Khin, et al.
The International Journal of Neuropsychopharmacology (2025)
Open Access | Times Cited: 1
Connectome-based predictive modeling of early and chronic psychosis symptoms
Maya L. Foster, Jean Ye, Albert R. Powers, et al.
Neuropsychopharmacology (2025)
Open Access | Times Cited: 1
Unraveling the Role of the Blood-Brain Barrier in the Pathophysiology of Depression: Recent Advances and Future Perspectives
Shamili Mariya Varghese, Shashikant Patel, Amritasree Nandan, et al.
Molecular Neurobiology (2024) Vol. 61, Iss. 12, pp. 10398-10447
Closed Access | Times Cited: 5
Conceptualization and characterization of “primary” and “secondary” cognitive impairment in schizophrenia
Antonio Vita, Gabriele Nibbio, Sergio Barlati
Psychiatry Research (2024) Vol. 340, pp. 116126-116126
Open Access | Times Cited: 5
MDMA for the Treatment of Negative Symptoms in Schizophrenia
Mitchell Arnovitz, Andrew J. Spitzberg, Ashkhan J. Davani, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 12, pp. 3255-3255
Open Access | Times Cited: 22
Assessment and Treatment of Negative Symptoms in Schizophrenia—A Regional Perspective
István Bitter, Pavel Mohr, Natalia Raspopova, et al.
Frontiers in Psychiatry (2022) Vol. 12
Open Access | Times Cited: 20
Major neurocognitive psychosis: a novel schizophrenia endophenotype class that is based on machine learning and resembles Kraepelin’s and Bleuler’s conceptions
Michaël Maes
Acta Neuropsychiatrica (2022) Vol. 35, Iss. 3, pp. 123-137
Open Access | Times Cited: 19
Using dimensionality-reduction techniques to understand the organization of psychotic symptoms in persistent psychotic illness and first episode psychosis
Leah Fleming, Ann Catherine Lemonde, David Benrimoh, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 11
Effect of cariprazine on attention and quality of life in patients with predominant negative symptoms of schizophrenia: A post-hoc analysis
Oloruntoba Oluboka, Andrea Bardell, Howard C. Margolese, et al.
Schizophrenia Research Cognition (2025) Vol. 40, pp. 100355-100355
Closed Access
Innovative Therapeutic Approaches in Severe Adolescent Depression: Neuroimaging and Pharmacological Insights
Andrei-Gabriel Zanfir, Simona Trifu
Balneo and PRM Research Journal (2025) Vol. 16, Iss. Vol 16 No. 1, pp. 765-765
Open Access
A review on the pharmacology of cariprazine and its role in the treatment of negative symptoms of schizophrenia
Panneer Selvan, Prashant Devkare, Arthik Shetty, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 3
Definition, assessment and treatment of cognitive impairment associated with schizophrenia: expert opinion and practical recommendations
Antonio Vita, Sergio Barlati, Roberto Cavallaro, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 3
Short-chain fatty acids in patients with schizophrenia and ultra-high risk population
Huiqing Peng, Lijun Ouyang, David Li, et al.
Frontiers in Psychiatry (2022) Vol. 13
Open Access | Times Cited: 15
Childhood Adversity and Incident Psychotic Experiences in Early Adulthood: Cognitive and Psychopathological Mediators
Andrea P. Cortés Hidalgo, Gemma Hammerton, Jon Heron, et al.
Schizophrenia Bulletin (2024) Vol. 50, Iss. 4, pp. 903-912
Open Access | Times Cited: 2
The Effect of an Emotion Recognition and Expression Program on the Alexithymia, Emotion Expression Skills and Positive and Negative Symptoms of Patients with Schizophrenia in a Community Mental Health Center
Adeviye Aydın, Berna Ersoy Özcan, Yunus Kaya
Issues in Mental Health Nursing (2024) Vol. 45, Iss. 5, pp. 528-536
Closed Access | Times Cited: 2
Assessing Executive Functioning in Schizophrenia: Concurrent and Discriminative Validity of a Novel Virtual Cooking Task
Asier Adriasola, Sergio Cervera‐Torres, Yolanda Cañada, et al.
Cyberpsychology Behavior and Social Networking (2024) Vol. 27, Iss. 8, pp. 571-581
Closed Access | Times Cited: 2
Integration of proteinogenic amino acids in the pathogenesis of schizophrenia
Michelle S. Carvalho, Maurício L. Sforça, Silvana A. Rocco, et al.
Medicine Advances (2024) Vol. 2, Iss. 2, pp. 123-135
Open Access | Times Cited: 2
Systematic Literature Review of Studies Reporting Measures of Functional Outcome or Quality of Life in People with Negative Symptoms of Schizophrenia
Dusica Hadzi Boskovic, Jayne Smith-Palmer, Johannes Pöhlmann, et al.
Patient Related Outcome Measures (2024) Vol. Volume 15, pp. 199-217
Open Access | Times Cited: 2
What Remains to Be Discovered in Schizophrenia Therapeutics: Contributions by Advancing the Molecular Mechanisms of Drugs for Psychosis and Schizophrenia
Christoph U. Correll, Massimo Tusconi, Mauro Giovanni Carta, et al.
Biomolecules (2024) Vol. 14, Iss. 8, pp. 906-906
Open Access | Times Cited: 2
Predictors of functioning in treatment-resistant schizophrenia: the role of negative symptoms and neurocognition
Yanhui Li, Mei San Ang, Jie Yin Yee, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 2
Uncovering convergence and divergence between autism and schizophrenia using genomic tools and patients’ neurons
Eva Romanovsky, Ashwani Choudhary, David Peles, et al.
Molecular Psychiatry (2024)
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top